Top Story

Phase 3 trial to study IV iron in patients with HFrEF begins enrollment

April 30, 2017

American Regent, a Daiichi Sankyo company, announced the first patients have been enrolled in a trial studying IV ferric carboxymaltose in individuals with HF with reduced ejection fraction and iron deficiency.

The study, HEART-FID, is a double blind, multicenter, randomized, placebo-controlled study of IV ferric carboxymaltose (Injectafer, American Regent) in patients with HFrEF and iron deficiency, according to a press release issued by the company.

Trial to study subcutaneous ICD in patients with diabetes, MI commences

April 29, 2017
An international trial to study the survival benefit of a subcutaneous implantable cardioverter defibrillator system has begun enrolling patients, according to a press…

Cardiology Today's Intervention highlights 5 articles relating to multivessel disease

April 28, 2017
Cardiology Today’s Intervention compiled a list stories posted to relating to interventions for patients with multivessel disease.
In the Journals

Blood test for patients with CAD symptoms may reduce unnecessary cardiac referrals

April 28, 2017
Patients with symptoms of obstructive CAD with a low score using a blood-based age/sex/gene expression test were less likely to be referred to a cardiologist, have…
In the JournalsPerspective

Secondary prevention treatments may benefit patients with MI, nonobstructive coronary arteries

April 28, 2017
Patients with MI but nonobstructive coronary arteries experienced long-term benefits from treatments, including statins and ACE inhibitors/angiotensin receptor
More News Headlines »